{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:57Z","timestamp":1792787937381,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China","award":["82203154"],"award-info":[{"award-number":["82203154"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["82573617"],"award-info":[{"award-number":["82573617"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Beijing Natural Science Foundation","award":["L248050"],"award-info":[{"award-number":["L248050"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["80102022501"],"award-info":[{"award-number":["80102022501"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02733-3","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:34:22Z","timestamp":1784115262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma proteomic and metabolomic profiling reveals molecular features relevant to neoadjuvant therapy response in locally advanced esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Chu","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpeng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianle","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2733_CR1","doi-asserted-by":"publisher","first-page":"e074962","DOI":"10.1136\/bmj-2023-074962","volume":"385","author":"N Deboever","year":"2024","unstructured":"Deboever N, Jones CM, Yamashita K, Ajani JA, Hofstetter W. L. Advances in diagnosis and management of cancer of the esophagus. BMJ. 2024;385:e074962. https:\/\/doi.org\/10.1136\/bmj-2023-074962.","journal-title":"BMJ"},{"key":"2733_CR2","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384. https:\/\/doi.org\/10.1056\/NEJMoa1112088.","journal-title":"N Engl J Med"},{"key":"2733_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/jco.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, et al. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin oncology: official J Am Soc Clin Oncol. 2021;39:1995\u20132004. https:\/\/doi.org\/10.1200\/jco.20.03614.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"2733_CR4","doi-asserted-by":"publisher","first-page":"108591","DOI":"10.1016\/j.pharmthera.2024.108591","volume":"254","author":"Z Yang","year":"2024","unstructured":"Yang Z, Guan F, Bronk L, Zhao L. Multi-omics approaches for biomarker discovery in predicting the response of esophageal cancer to neoadjuvant therapy: A multidimensional perspective. Pharmacol Ther. 2024;254:108591. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108591.","journal-title":"Pharmacol Ther"},{"key":"2733_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2025.0220","volume":"160","author":"X Guo","year":"2025","unstructured":"Guo X, et al. Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma. JAMA Surg. 2025;160:565\u201374. https:\/\/doi.org\/10.1001\/jamasurg.2025.0220.","journal-title":"JAMA Surg"},{"key":"2733_CR6","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","volume":"30","author":"J Qin","year":"2024","unstructured":"Qin J, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nat Med. 2024;30:2549\u201357. https:\/\/doi.org\/10.1038\/s41591-024-03064-w.","journal-title":"Nat Med"},{"key":"2733_CR7","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1038\/s41591-023-02469-3","volume":"29","author":"J Yin","year":"2023","unstructured":"Yin J, et al. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2023;29:2068\u201378. https:\/\/doi.org\/10.1038\/s41591-023-02469-3.","journal-title":"Nat Med"},{"key":"2733_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s0140-6736(24)01084-5","volume":"404","author":"SE Al-Batran","year":"2024","unstructured":"Al-Batran SE, Koch C. Neoadjuvant therapy for oesophageal cancer: refining the armamentarium. Lancet (London England). 2024;404:5\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(24)01084-5.","journal-title":"Lancet (London England)"},{"key":"2733_CR9","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1200\/jco.2005.05.017","volume":"23","author":"AC Berger","year":"2005","unstructured":"Berger AC, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330\u20137. https:\/\/doi.org\/10.1200\/jco.2005.05.017.","journal-title":"J Clin Oncol"},{"key":"2733_CR10","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.jtho.2016.07.031","volume":"11","author":"P Samson","year":"2016","unstructured":"Samson P, et al. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients. J Thorac Oncol. 2016;11:2227\u201337. https:\/\/doi.org\/10.1016\/j.jtho.2016.07.031.","journal-title":"J Thorac Oncol"},{"key":"2733_CR11","doi-asserted-by":"publisher","first-page":"e162743","DOI":"10.1001\/jamasurg.2016.2743","volume":"151","author":"KR Haisley","year":"2016","unstructured":"Haisley KR, et al. Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal Cancer. JAMA Surg. 2016;151:e162743. https:\/\/doi.org\/10.1001\/jamasurg.2016.2743.","journal-title":"JAMA Surg"},{"key":"2733_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","volume":"15","author":"J Hu","year":"2023","unstructured":"Hu J, et al. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med. 2023;15:14. https:\/\/doi.org\/10.1186\/s13073-023-01164-9.","journal-title":"Genome Med"},{"key":"2733_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, et al. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. JAMA Oncol. 2024;10:227\u201335. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5033.","journal-title":"JAMA Oncol"},{"key":"2733_CR14","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/jco-25-00883","volume":"43","author":"J He","year":"2025","unstructured":"He J, et al. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. J Clin oncology: official J Am Soc Clin Oncol. 2025;43:2875\u201387. https:\/\/doi.org\/10.1200\/jco-25-00883.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"2733_CR15","doi-asserted-by":"publisher","first-page":"102251","DOI":"10.1016\/j.xcrm.2025.102251","volume":"6","author":"L Huang","year":"2025","unstructured":"Huang L, et al. Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer. Cell Rep Med. 2025;6:102251. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102251.","journal-title":"Cell Rep Med"},{"key":"2733_CR16","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu Z, et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell. 2025;188:3081\u2013e30963019. https:\/\/doi.org\/10.1016\/j.cell.2025.03.018.","journal-title":"Cell"},{"key":"2733_CR17","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.annonc.2025.03.019","volume":"36","author":"C Valenza","year":"2025","unstructured":"Valenza C, et al. Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis. Annals oncology: official J Eur Soc Med Oncol. 2025;36:726\u201336. https:\/\/doi.org\/10.1016\/j.annonc.2025.03.019.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"key":"2733_CR18","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s43018-025-00990-7","volume":"6","author":"G Awada","year":"2025","unstructured":"Awada G, et al. The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types. Nat cancer. 2025;6:967\u201387. https:\/\/doi.org\/10.1038\/s43018-025-00990-7.","journal-title":"Nat cancer"},{"key":"2733_CR19","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.ccell.2023.09.011","volume":"41","author":"Z Liu","year":"2023","unstructured":"Liu Z, et al. Progenitor-like exhausted SPRY1(+)CD8(+) T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer Cell. 2023;41:1852\u2013e18701859. https:\/\/doi.org\/10.1016\/j.ccell.2023.09.011.","journal-title":"Cancer Cell"},{"key":"2733_CR20","doi-asserted-by":"publisher","first-page":"9097","DOI":"10.1038\/s41467-024-52977-0","volume":"15","author":"Z Yang","year":"2024","unstructured":"Yang Z, et al. Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. Nat Commun. 2024;15:9097. https:\/\/doi.org\/10.1038\/s41467-024-52977-0.","journal-title":"Nat Commun"},{"key":"2733_CR21","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","volume":"41","author":"SL Topalian","year":"2023","unstructured":"Topalian SL, et al. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy. Cancer Cell. 2023;41:1551\u201366. https:\/\/doi.org\/10.1016\/j.ccell.2023.07.011.","journal-title":"Cancer Cell"},{"key":"2733_CR22","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1038\/s41467-024-48480-1","volume":"15","author":"W Beckabir","year":"2024","unstructured":"Beckabir W, et al. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. Nat Commun. 2024;15:4448. https:\/\/doi.org\/10.1038\/s41467-024-48480-1.","journal-title":"Nat Commun"},{"key":"2733_CR23","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ccell.2024.07.005","volume":"42","author":"Y Sun","year":"2024","unstructured":"Sun Y, et al. Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers. Cancer Cell. 2024;42:1386\u2013e14001388. https:\/\/doi.org\/10.1016\/j.ccell.2024.07.005.","journal-title":"Cancer Cell"},{"key":"2733_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cell.2024.10.045","volume":"188","author":"YT Deng","year":"2025","unstructured":"Deng YT, et al. Atlas of the plasma proteome in health and disease in 53,026 adults. Cell. 2025;188:253\u2013e271257. https:\/\/doi.org\/10.1016\/j.cell.2024.10.045.","journal-title":"Cell"},{"key":"2733_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat Med. 2024;30:1023\u201334. https:\/\/doi.org\/10.1038\/s41591-024-02877-z.","journal-title":"Nat Med"},{"key":"2733_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-024-02006-x","volume":"23","author":"P Yue","year":"2024","unstructured":"Yue P, et al. Minimal residual disease profiling predicts pathological complete response in esophageal squamous cell carcinoma. Mol Cancer. 2024;23:96. https:\/\/doi.org\/10.1186\/s12943-024-02006-x.","journal-title":"Mol Cancer"},{"key":"2733_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-023-06877-w","volume":"629","author":"Temporal dynamics of the","year":"2024","unstructured":"Temporal dynamics of the. multi-omic response to endurance exercise training. Nature. 2024;629:174\u201383. https:\/\/doi.org\/10.1038\/s41586-023-06877-w.","journal-title":"Nature"},{"key":"2733_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12943-025-02482-9","volume":"24","author":"M Yu","year":"2025","unstructured":"Yu M, et al. Purine metabolism: a pan-cancer metabolic dysregulation across circulation and tissues. Mol Cancer. 2025;24:255. https:\/\/doi.org\/10.1186\/s12943-025-02482-9.","journal-title":"Mol Cancer"},{"key":"2733_CR29","doi-asserted-by":"publisher","unstructured":"\u00d6gren J, et al. Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers. Mol Cancer. 2026;25. https:\/\/doi.org\/10.1186\/s12943-026-02654-1.","DOI":"10.1186\/s12943-026-02654-1"},{"key":"2733_CR30","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.cell.2020.07.040","volume":"182","author":"JM Wozniak","year":"2020","unstructured":"Wozniak JM, et al. Mortality Risk Profiling of Staphylococcus aureus Bacteremia by Multi-omic Serum Analysis Reveals Early Predictive and Pathogenic Signatures. Cell. 2020;182:1311\u2013e13271314. https:\/\/doi.org\/10.1016\/j.cell.2020.07.040.","journal-title":"Cell"},{"key":"2733_CR31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-25-1449","author":"ZY Qian","year":"2026","unstructured":"Qian ZY, et al. Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy. Cancer Discov. 2026. https:\/\/doi.org\/10.1158\/2159-8290.Cd-25-1449.","journal-title":"Cancer Discov"},{"key":"2733_CR32","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9:e95192. https:\/\/doi.org\/10.1371\/journal.pone.0095192.","journal-title":"PLoS ONE"},{"key":"2733_CR33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/cac2.12066","volume":"40","author":"T Huang","year":"2020","unstructured":"Huang T, Yang J, Liu B, Fu L. A new mouse esophageal cancer cell line (mEC25)-derived pre-clinical syngeneic tumor model for immunotherapy. Cancer Commun (London England). 2020;40:316\u201320. https:\/\/doi.org\/10.1002\/cac2.12066.","journal-title":"Cancer Commun (London England)"},{"key":"2733_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-025-09873-0","volume":"36","author":"I Ahmed","year":"2025","unstructured":"Ahmed I, Mohamed A, Savari O, Xue Y, Asa SL. Expression of DLL3 and SEZ6 in the Spectrum of Neuroendocrine Neoplasia. Endocr Pathol. 2025;36:27. https:\/\/doi.org\/10.1007\/s12022-025-09873-0.","journal-title":"Endocr Pathol"},{"key":"2733_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12916-023-02804-y","volume":"21","author":"Y Li","year":"2023","unstructured":"Li Y, et al. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial: A randomized clinical trial of neoadjuvant therapy for ESCC. BMC Med. 2023;21:86. https:\/\/doi.org\/10.1186\/s12916-023-02804-y.","journal-title":"BMC Med"},{"key":"2733_CR36","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s42255-024-01059-y","volume":"6","author":"SA Barritt","year":"2024","unstructured":"Barritt SA, DuBois-Coyne SE, Dibble CC, Coenzyme. A biosynthesis: mechanisms of regulation, function and disease. Nat metabolism. 2024;6:1008\u201323. https:\/\/doi.org\/10.1038\/s42255-024-01059-y.","journal-title":"Nat metabolism"},{"key":"2733_CR37","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.cmet.2021.11.010","volume":"33","author":"M St Paul","year":"2021","unstructured":"St Paul M, et al. Coenzyme A fuels T cell anti-tumor immunity. Cell Metabol. 2021;33:2415\u2013e24272416. https:\/\/doi.org\/10.1016\/j.cmet.2021.11.010.","journal-title":"Cell Metabol"},{"key":"2733_CR38","doi-asserted-by":"publisher","first-page":"e07705","DOI":"10.1002\/advs.202507705","volume":"13","author":"D Chen","year":"2026","unstructured":"Chen D, et al. Single-Cell Transcriptome Atlas Reveals the Underlying Mechanism of Kynurenic Acid in the Regulation of Tumor Immune Microenvironment in Glioblastoma. Advanced science (Weinheim. Baden-Wurttemberg Germany). 2026;13:e07705. https:\/\/doi.org\/10.1002\/advs.202507705.","journal-title":"Baden-Wurttemberg Germany)"},{"key":"2733_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s40364-025-00835-6","volume":"13","author":"W Chen","year":"2025","unstructured":"Chen W, et al. Neurotransmitters in tumors: chemical cross-talk shaping tumor progression. Biomark Res. 2025;13:125. https:\/\/doi.org\/10.1186\/s40364-025-00835-6.","journal-title":"Biomark Res"},{"key":"2733_CR40","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.cell.2024.03.011","volume":"187","author":"T Cao","year":"2024","unstructured":"Cao T, et al. Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8(+) T cells. Cell. 2024;187:2288\u2013e23042227. https:\/\/doi.org\/10.1016\/j.cell.2024.03.011.","journal-title":"Cell"},{"key":"2733_CR41","doi-asserted-by":"publisher","unstructured":"Xiao H et al. Taurine Inhibits Ferroptosis Mediated by the Crosstalk between Tumor Cells and Tumor-Associated Macrophages in Prostate Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11, e2303894. https:\/\/doi.org\/10.1002\/advs.202303894 (2024).","DOI":"10.1002\/advs.202303894"},{"key":"2733_CR42","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.Cd-23-0334","volume":"14","author":"C He","year":"2024","unstructured":"He C, et al. Vitamin B6 Competition in the Tumor Microenvironment Hampers Antitumor Functions of NK Cells. Cancer Discov. 2024;14:176\u201393. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-0334.","journal-title":"Cancer Discov"},{"key":"2733_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"key":"2733_CR44","doi-asserted-by":"publisher","first-page":"113773","DOI":"10.1016\/j.celrep.2024.113773","volume":"43","author":"J Giraud","year":"2024","unstructured":"Giraud J, et al. THBS1(+) myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1. Cell Rep. 2024;43:113773. https:\/\/doi.org\/10.1016\/j.celrep.2024.113773.","journal-title":"Cell Rep"},{"key":"2733_CR45","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13046-024-03178-6","volume":"43","author":"H Luo","year":"2024","unstructured":"Luo H, et al. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. J experimental Clin cancer research: CR. 2024;43:258. https:\/\/doi.org\/10.1186\/s13046-024-03178-6.","journal-title":"J experimental Clin cancer research: CR"},{"key":"2733_CR46","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/jlb.49.3.258","volume":"49","author":"EJ Leonard","year":"1991","unstructured":"Leonard EJ, et al. Chemotactic activity and receptor binding of neutrophil attractant\/activation protein-1 (NAP-1) and structurally related host defense cytokines: interaction of NAP-2 with the NAP-1 receptor. J Leukoc Biol. 1991;49:258\u201365. https:\/\/doi.org\/10.1002\/jlb.49.3.258.","journal-title":"J Leukoc Biol"},{"key":"2733_CR47","doi-asserted-by":"publisher","first-page":"114828","DOI":"10.1016\/j.intimp.2025.114828","volume":"158","author":"X Yang","year":"2025","unstructured":"Yang X, et al. Targeting neutrophil extracellular traps: SERPINE1 and THBS1 as non-invasive biomarkers for early detection of liver fibrosis in metabolic dysfunction-associated Steatotic liver disease. Int Immunopharmacol. 2025;158:114828. https:\/\/doi.org\/10.1016\/j.intimp.2025.114828.","journal-title":"Int Immunopharmacol"},{"key":"2733_CR48","doi-asserted-by":"publisher","unstructured":"Neumann U, Genze N, Heider D. EFS: an ensemble feature selection tool implemented as R-package and web-application. BioData Min. 2017;10. https:\/\/doi.org\/10.1186\/s13040-017-0142-8.","DOI":"10.1186\/s13040-017-0142-8"},{"key":"2733_CR49","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.Cd-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer Y, et al. Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer. Cancer Discov. 2020;10:1330\u201351. https:\/\/doi.org\/10.1158\/2159-8290.Cd-19-1384.","journal-title":"Cancer Discov"},{"key":"2733_CR50","doi-asserted-by":"publisher","first-page":"217475","DOI":"10.1016\/j.canlet.2025.217475","volume":"612","author":"R Wei","year":"2025","unstructured":"Wei R, et al. FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity. Cancer Lett. 2025;612:217475. https:\/\/doi.org\/10.1016\/j.canlet.2025.217475.","journal-title":"Cancer Lett"},{"key":"2733_CR51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1600-065X.2011.01082.x","volume":"245","author":"RI Lehrer","year":"2012","unstructured":"Lehrer RI, Lu W. \u03b1-Defensins in human innate immunity. Immunol Rev. 2012;245:84\u2013112. https:\/\/doi.org\/10.1111\/j.1600-065X.2011.01082.x.","journal-title":"Immunol Rev"},{"key":"2733_CR52","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1053\/j.gastro.2024.03.007","volume":"167","author":"D Yang","year":"2024","unstructured":"Yang D, et al. Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy. Gastroenterology. 2024;167:298\u2013314. https:\/\/doi.org\/10.1053\/j.gastro.2024.03.007.","journal-title":"Gastroenterology"},{"key":"2733_CR53","doi-asserted-by":"publisher","unstructured":"Scafetta G, D\u2019Alessandria C, Bartolazzi A. Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape. J experimental Clin cancer research: CR. 2024;43. https:\/\/doi.org\/10.1186\/s13046-024-02968-2.","DOI":"10.1186\/s13046-024-02968-2"},{"key":"2733_CR54","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00404-019-05292-9","volume":"300","author":"I Boutas","year":"2019","unstructured":"Boutas I, et al. The expression of galectin-3 in breast cancer and its association with chemoresistance: a systematic review of the literature. Arch Gynecol Obstet. 2019;300:1113\u201320. https:\/\/doi.org\/10.1007\/s00404-019-05292-9.","journal-title":"Arch Gynecol Obstet"},{"key":"2733_CR55","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1470-2045(25)00027-0","volume":"26","author":"BJ van der Wilk","year":"2025","unstructured":"van der Wilk BJ, et al. Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2025;26:425\u201336. https:\/\/doi.org\/10.1016\/s1470-2045(25)00027-0.","journal-title":"Lancet Oncol"},{"key":"2733_CR56","doi-asserted-by":"publisher","unstructured":"Ji G, et al. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma. Genome Med. 2024;16. https:\/\/doi.org\/10.1186\/s13073-024-01320-9.","DOI":"10.1186\/s13073-024-01320-9"},{"key":"2733_CR57","doi-asserted-by":"publisher","first-page":"101096","DOI":"10.1016\/j.drup.2024.101096","volume":"76","author":"H Zhang","year":"2024","unstructured":"Zhang H, et al. KLF12 interacts with TRIM27 to affect cisplatin resistance and cancer metastasis in esophageal squamous cell carcinoma by regulating L1CAM expression. Drug Resist Updat. 2024;76:101096. https:\/\/doi.org\/10.1016\/j.drup.2024.101096.","journal-title":"Drug Resist Updat"},{"key":"2733_CR58","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13058-024-01813-w","volume":"26","author":"N Zhang","year":"2024","unstructured":"Zhang N, et al. Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2\u2009+\u2009breast cancer. Breast cancer research: BCR. 2024;26:64. https:\/\/doi.org\/10.1186\/s13058-024-01813-w.","journal-title":"Breast cancer research: BCR"},{"key":"2733_CR59","doi-asserted-by":"publisher","first-page":"6474","DOI":"10.1038\/s41467-025-61685-2","volume":"16","author":"C Tang","year":"2025","unstructured":"Tang C, et al. Immunodiagnostic plasma amino acid residue biomarkers detect cancer early and predict treatment response. Nat Commun. 2025;16:6474. https:\/\/doi.org\/10.1038\/s41467-025-61685-2.","journal-title":"Nat Commun"},{"key":"2733_CR60","doi-asserted-by":"publisher","unstructured":"Xiong G, et al. CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2023-008662.","DOI":"10.1136\/jitc-2023-008662"},{"key":"2733_CR61","doi-asserted-by":"publisher","unstructured":"Feng T, et al. Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-008942.","DOI":"10.1136\/jitc-2024-008942"},{"key":"2733_CR62","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","volume":"186","author":"J Gungabeesoon","year":"2023","unstructured":"Gungabeesoon J, et al. A neutrophil response linked to tumor control in immunotherapy. Cell. 2023;186:1448\u2013e14641420. https:\/\/doi.org\/10.1016\/j.cell.2023.02.032.","journal-title":"Cell"},{"key":"2733_CR63","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","volume":"12","author":"C Valero","year":"2021","unstructured":"Valero C, et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021;12:729. https:\/\/doi.org\/10.1038\/s41467-021-20935-9.","journal-title":"Nat Commun"},{"key":"2733_CR64","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.immuni.2025.03.002","volume":"58","author":"L Yu","year":"2025","unstructured":"Yu L, et al. Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer. Immunity. 2025;58:909\u2013e925907. https:\/\/doi.org\/10.1016\/j.immuni.2025.03.002.","journal-title":"Immunity"},{"key":"2733_CR65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","volume":"569","author":"F Veglia","year":"2019","unstructured":"Veglia F, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 2019;569:73\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1118-2.","journal-title":"Nature"},{"key":"2733_CR66","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1158\/0008-5472.Can-04-0465","volume":"64","author":"PC Rodriguez","year":"2004","unstructured":"Rodriguez PC, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64:5839\u201349. https:\/\/doi.org\/10.1158\/0008-5472.Can-04-0465.","journal-title":"Cancer Res"},{"key":"2733_CR67","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.devcel.2025.10.017","volume":"61","author":"J Wu","year":"2026","unstructured":"Wu J, et al. Vitamin B6 preserves the stemness-like phenotypes and antitumor ability of CD8(+) T cells. Dev Cell. 2026;61:589\u2013e604587. https:\/\/doi.org\/10.1016\/j.devcel.2025.10.017.","journal-title":"Dev Cell"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02733-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02733-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02733-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:24:37Z","timestamp":1792056277000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02733-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2733"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02733-3","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Ethics Committee of the National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (25\/041-4987). Written informed consent was obtained from all participants.The animal experiments were carried out in compliance with the ethical guidelines of the International Council for Laboratory Animal Science (ICLAS) and were approved by the Institutional Animal Care and Use Committee of the National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (NCC2022A029).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"237"}}